Stockholm - Free Realtime Quote SEK

Alligator Bioscience AB (publ) (ATORX.ST)

4.0000

0.0000

(0.00%)

As of 12:29:43 PM GMT+2. Market Open.

Alligator Bioscience Announces Paediatric Study Waiver for Mitazalimab Granted by the European Medicines Agency

LUND, SE / ACCESS Newswire / May 20, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical stage biotechnology company pioneering immuno-oncology therapeutics, today announced that the European Medicines Agency (EMA) has granted a waiver ...

ACCESS Newswire 21 hours ago

ATORX.ST
0.00%
Alligator Bioscience AB Announces Preliminary Outcome of Exercise of Warrants Series TO 12

LUND, SE / ACCESS Newswire / May 20, 2025 / Alligator Bioscience (STO:ATORX) NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, ...

ACCESS Newswire 23 hours ago

ATORX.ST
0.00%
Last Day of Trading in Warrants Series TO 12 in Alligator Bioscience is 15 May 2025

LUND, SE / ACCESS Newswire / May 15, 2025 / Alligator Bioscience (STO:ATORX) NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, ...

ACCESS Newswire 6 days ago

ATORX.ST
0.00%
Alligator Bioscience to Attend ASCO 2025 Annual Meeting

LUND, SE / ACCESS Newswire / May 12, 2025 /Alligator Bioscience (Nasdaq Stockholm:ATORX) is pleased to announce that data from its OPTIMIZE-1 clinical trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. ...

ACCESS Newswire 9 days ago

ATORX.ST
0.00%
Alligator Bioscience Announces that 85% of the Warrant Programme TO 12 has Been Secured and that the Outstanding Loan has Been Renegotiated

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH ...

ACCESS Newswire 11 days ago

ATORX.ST
0.00%
Alligator Bioscience Completes Phase 3 GMP Manufacturing of Mitazalimab, Remains on Track for Trial Initiation with Partner

LUND, SE / ACCESS Newswire / May 9, 2025 /Alligator Bioscience (Nasdaq Stockholm:ATORX) today announced the successful completion of the manufacture of the first GMP drug product batch of its lead asset mitazalimab using a new improved commercial-scale ...

ACCESS Newswire 12 days ago

ATORX.ST
0.00%
Alligator Bioscience Updates Dividend Policy

LUND, SE / ACCESS Newswire / May 8, 2025 / Alligator Bioscience (STO:ATORX) - Alligator Bioscience AB (publ) today announces an update to its dividend policy following the constitution of Alligator's new Board of Directors on 7 May 2025. The updated ...

ACCESS Newswire 13 days ago

ATORX.ST
0.00%
Bulletin from the Annual General Meeting in Alligator Bioscience AB on 7 May 2025

LUND, SE / ACCESS Newswire / May 7, 2025 / Alligator Bioscience (STO:ATORX) - The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. Today, ...

ACCESS Newswire 14 days ago

ATORX.ST
0.00%
Change in Number of Shares and Votes in Alligator Bioscience AB

LUND, SWEDEN / ACCESS Newswire / April 30, 2025 / During April 2025, the number of shares and votes in Alligator Bioscience AB (STO:ATORX) ("Alligator Bioscience") has decreased as a result of the redemption of all 779,169 outstanding series C shares, ...

ACCESS Newswire 20 days ago

ATORX.ST
0.00%
Exercise Price Determined for the Exercise of Warrants Series TO 12 in Alligator Bioscience AB

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH ...

ACCESS Newswire 22 days ago

ATORX.ST
0.00%
Alligator Bioscience AB Reports Financial Results for Q1 2025 and Provides a Business Update

LUND, SE / ACCESS Newswire / April 24, 2025 / Alligator Bioscience (STO:ATORX) 24-month data from OPTIMIZE-1 show 29.4% survival rate for mitazalimab-three times higher than chemotherapy alone FDA alignment secured on Phase 3 strategy following successful ...

ACCESS Newswire 27 days ago

ATORX.ST
0.00%
Alligator Bioscience Announces Initiation of HLX22 Phase 2 Trial in Breast Cancer by Shanghai Henlius Biotech, Inc.

LUND, SE / ACCESS Newswire / April 23, 2025 /Alligator Bioscience (Nasdaq Stockholm:ATORX) today announces that Shanghai Henlius Biotech, Inc. ("Henlius") has initiated a Phase 2 clinical trial with HLX22, an anti-HER2 monoclonal antibody originally ...

ACCESS Newswire 28 days ago

ATORX.ST
0.00%
Notice of Annual General Meeting in Alligator Bioscience AB

LUND, SE / ACCESS Newswire / April 2, 2025 / Alligator Bioscience (STO:ATORX) - The shareholders of Alligator Bioscience AB, Reg. No. 556597-8201, are invited to the annual general meeting to be held on Wednesday 7 May 2025, at 10.00 a.m CEST at Medicon ...

ACCESS Newswire last month

ATORX.ST
0.00%
Alligator Bioscience Determines Record Date for Reverse Share Split of Ordinary Shares and Reminds of the Recalculation of Warrants

LUND, SWEDEN / ACCESS Newswire / April 1, 2025 / Alligator Bioscience (STO:ATORX) - The board of directors of Alligator Bioscience AB ("Alligator Bioscience" or the "Company") has resolved that the record date for the reverse share split of ordinary ...

ACCESS Newswire last month

ATORX.ST
0.00%
Alligator Bioscience Publishes Annual Report for 2024

LUND, SWEDEN / ACCESS Newswire / March 27, 2025 / Alligator Bioscience (STO:ATORX) today announced that the Annual Report for 2024, as well as the company's Remuneration Report, has been published. Because of environmental and cost reasons, Alligator ...

ACCESS Newswire last month

ATORX.ST
0.00%
Bulletin from the Extraordinary General Meeting in Alligator Bioscience AB

LUND, SWEDEN / ACCESS Newswire / March 27, 2025 /Alligator Bioscience (STO:ATORX) Today, on 27 March 2025, an extraordinary general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follows below. Resolution on guidelines ...

ACCESS Newswire last month

ATORX.ST
0.00%
Alligator Bioscience Announces Leadership Transition in Clinical Development

LUND, SWEDEN / ACCESS Newswire / March 21, 2025 /Alligator Bioscience (Nasdaq Stockholm:ATORX) today announces that Dr. Sumeet Ambarkhane MD, Chief Medical Officer, will be leaving Alligator by end of March 2025. Dr. Ambarkhane has played a key role ...

ACCESS Newswire last month

ATORX.ST
0.00%
Alligator Bioscience Announces FDA Orphan Drug Designation for HLX22/AC101 in Gastric Cancer

LUND, SE / ACCESS Newswire / March 20, 2025 /Alligator Bioscience (Nasdaq Stockholm:ATORX) today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to HLX22 (AC101), an anti-HER2 monoclonal antibody, ...

ACCESS Newswire last month

ATORX.ST
0.00%
Alligator Bioscience Announces Continued Encouraging Overall Survival Benefit for Mitazalimab

Results show a 24-month survival rate of 29.4% for mitazalimab in combination with mFOLFIRINOX, triple that of chemotherapy alone Topline data from the 450 µg/kg cohort, further strengthens the rationale for 900 µg/kg as the Phase 3 dose ...

ACCESS Newswire 2 months ago

ATORX.ST
0.00%
Notice of Extraordinary General Meeting in Alligator Bioscience AB

LUND, SWEDEN / ACCESS Newswire / February 25, 2025 / Alligator Bioscience (STO:ATORX) The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. ...

ACCESS Newswire 2 months ago

ATORX.ST
0.00%

Performance Overview

Return	ATORX.ST	OMX Stockholm 30 Index (^OMX)
YTD	-81.00%	+1.60%
1-Year	-94.79%	-4.13%
3-Year	-95.02%	+26.51%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Alligator Bioscience AB (publ) (ATORX.ST)

Alligator Bioscience Announces Paediatric Study Waiver for Mitazalimab Granted by the European Medicines Agency

Alligator Bioscience AB Announces Preliminary Outcome of Exercise of Warrants Series TO 12

Last Day of Trading in Warrants Series TO 12 in Alligator Bioscience is 15 May 2025

Alligator Bioscience to Attend ASCO 2025 Annual Meeting

Alligator Bioscience Announces that 85% of the Warrant Programme TO 12 has Been Secured and that the Outstanding Loan has Been Renegotiated

Alligator Bioscience Completes Phase 3 GMP Manufacturing of Mitazalimab, Remains on Track for Trial Initiation with Partner

Alligator Bioscience Updates Dividend Policy

Bulletin from the Annual General Meeting in Alligator Bioscience AB on 7 May 2025

Change in Number of Shares and Votes in Alligator Bioscience AB

Exercise Price Determined for the Exercise of Warrants Series TO 12 in Alligator Bioscience AB

Alligator Bioscience AB Reports Financial Results for Q1 2025 and Provides a Business Update

Alligator Bioscience Announces Initiation of HLX22 Phase 2 Trial in Breast Cancer by Shanghai Henlius Biotech, Inc.

Notice of Annual General Meeting in Alligator Bioscience AB

Alligator Bioscience Determines Record Date for Reverse Share Split of Ordinary Shares and Reminds of the Recalculation of Warrants

Alligator Bioscience Publishes Annual Report for 2024

Bulletin from the Extraordinary General Meeting in Alligator Bioscience AB

Alligator Bioscience Announces Leadership Transition in Clinical Development

Alligator Bioscience Announces FDA Orphan Drug Designation for HLX22/AC101 in Gastric Cancer

Alligator Bioscience Announces Continued Encouraging Overall Survival Benefit for Mitazalimab

Notice of Extraordinary General Meeting in Alligator Bioscience AB

Performance Overview